NCT07122089 - Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2026

Primary Completion Date

January 2, 2030

Study Completion Date

January 2, 2030

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DEVICE

Selective Internal Radiotherapy

SIRT will use Yttrium-90 glass-microspheres (TheraSphereTM). SIRT needs two steps: the treatment simulation (diagnostic angiography and scintigraphy of hepatic perfusion with 99mTc-MAA) and the administration (during a therapeutic angiography).

DRUG

Tremelimumab

Tremelimumab should be done 1 to 3 weeks after SIRT and is administrated according to the Summary of Product Characteristic (SPC).

DRUG

Durvalumab

After the end of the tremelimumab infusion, patient receive durvalumab then one injection every 4 weeks until further progression upon investigator decision. Also administrated according to the Summary of Product Characteristic (SPC).